Results 1 to 10 of about 75,291 (186)

Benefit and safety of capecitabine after resection of biliary tract cancer: a real-world study with propensity score matching [PDF]

Frontiers in Oncology
Biliary tract cancer (BTC) is a high mortality disease, with few patients eligible for resection. Even post-surgery, recurrence rates remain high. The benefit of capecitabine as adjuvant therapy is uncertain, as seen in the BILCAP trial results.
Hugo Roussel, Sophie Le Joncour, Valerie Aurillac, Arthur Marichez, Jean Frederic Blanc, Laurence Chiche, Christophe Laurent, Marie Decraecker   +7 more
doaj   +2 more sources

A phase IB and randomised phase IIA trial of CApecitabine plus Radium-223 (Xofigo™) in breast cancer patients with BONe metastases: CARBON trial results

Journal of Bone Oncology, 2022
Background: Approximately 70% of patients with metastatic breast cancer (MBC) develop bone metastases. Despite advances in systemic treatment options and the use of bone targeted agents in the management of bone metastases to reduce skeletal morbidity ...
Matthew Winter, Rob Coleman, Jessica Kendall, Carlo Palmieri, Chris Twelves, Sacha Howell, Iain MacPherson, Caroline Wilson, Kash Purohit, Jacqui Gath, Christine Taylor, Richard Eastell, Geraldine Murden, Sarah R. Brown, Emma Rathbone, Janet Brown   +15 more
doaj   +1 more source

Utility of patient-derived lymphoblastoid cell lines as an ex vivo capecitabine sensitivity prediction model for breast cancer patients. [PDF]

, 2016
Capecitabine is commonly used in treating breast cancer; however, therapeutic response varies among patients and there is no clinically validated model to predict individual outcomes.
Abramson, Vandana, Forero, Andres, Huang, R Stephanie, LaCroix, Bonnie, Lenkala, Divya, Morrison, Gladys, Morrow, Phuong Khanh, Nanda, Rita, O'Donnell, Peter H, Rugo, Hope S, Van Poznak, Catherine, Ziliak, Dana   +11 more
core   +9 more sources

In vitro anti-proliferative effect of capecitabine (Xeloda) combined with mocetinostat (MGCD0103) in 4T1 breast cancer cell line by immunoblotting [PDF]

Iranian Journal of Basic Medical Sciences, 2021
Objective(s): Mouse breast cancer cell line 4T1 can accurately mimic the response to immune receptors and targeting therapeutic agents. Combined therapy has emerged as an important strategy with reduced side effects and maximum therapeutic effect ...
Hacer Kaya Cakır, Onur Eroglu
doaj   +1 more source

Case Report: Various Abnormalities in Lipid and Glucose Metabolism Induced by Capecitabine

Frontiers in Oncology, 2021
Capecitabine has been used for the treatment of various types of tumors. The rare side effects induced by capecitabine have been reported as hypertriglyceridemia, acute pancreatitis associated with hypertriglyceridemia and hypertriglyceridemia ...
Takatoshi Anno, Tomoki Yamatsuji, Koichi Tomoda, Shuhei Nakanishi, Hideaki Kaneto   +4 more
doaj   +1 more source

The Clinical Value of Chemotherapy Combined With Capecitabine in Triple-Negative Breast Cancer—A Meta-Analysis

Frontiers in Pharmacology, 2021
Purpose: Triple-negative breast cancer (TNBC) is the most dangerous subtype of breast cancer with high rates of metastasis and recurrence. The efficacy of capecitabine in chemotherapy for TNBC is still controversial. This study evaluated the efficacy and
Zilin Zhang, Kai Ma, Jing Li, Yeneng Guan, Chaobo Yang, Aqin Yan, Hongda Zhu   +6 more
doaj   +1 more source

Glembatumumab vedotin for patients with metastatic, gpNMB overexpressing, triple-negative breast cancer (“METRIC”): a randomized multicenter study

npj Breast Cancer, 2021
The METRIC study (NCT#0199733) explored a novel antibody–drug conjugate, glembatumumab vedotin (GV), targeting gpNMB that is overexpressed in ~40% of patients with triple-negative breast cancer (TNBC) and associated with poor prognosis.
Linda T. Vahdat, Peter Schmid, Andres Forero-Torres, Kimberly Blackwell, Melinda L. Telli, Michelle Melisko, Volker Möbus, Javier Cortes, Alberto J. Montero, Cynthia Ma, Rita Nanda, Gail S. Wright, Yi He, Thomas Hawthorne, Rebecca G. Bagley, Abdel-Baset Halim, Christopher D. Turner, Denise A. Yardley   +17 more
doaj   +1 more source

Concomitant Administration of Capecitabine and Folate Supplements: Need to Encourage Medication Reconciliation

Pharmaceuticals, 2022
Hand-Foot syndrome (HFS) and diarrhoea are dose-limiting Adverse Drug Reactions (ADRs) of capecitabine-based chemotherapy. Four polymorphisms in the dihydropyrimidine dehydrogenase (DPYD) gene, encoding the DPD enzyme responsible for the metabolism of ...
Berenice Stefanelli, Carmine Sellitto, Emanuela De Bellis, Martina Torsiello, Nicola Bertini, Angelo Maria Pezzullo, Graziamaria Corbi, Francesco Sabbatino, Stefano Pepe, Angela Tesse, Valeria Conti, Amelia Filippelli   +11 more
doaj   +1 more source

Analysis of capecitabine metabolites in conjunction with digital autoradiography in a murine model of pancreatic cancer suggests extensive drug penetration through the tumor

Pharmacology Research & Perspectives, 2022
Previously published digital autoradiography of 3H‐labeled capecitabine reveals a near‐uniform distribution of activity throughout a murine pancreatic model.
James Russell, Louise Fanchon, Hanan Alwaseem, Henrik Molina, Isabella O’Donoghue, Amber Bahr, Elisa deStanchina, Nagavarakishore Pillarsetty, John L. Humm   +8 more
doaj   +1 more source

Drug-Induced Liver Injury Caused by Capecitabine: A Case Report and a Literature Review

Case Reports in Oncology, 2023
Chemotherapy is widely used in cancer treatment, and the drug Capecitabine is often used in treatment of breast cancer and usually well-tolerated. Toxicity from Capecitabine typically involves hand-foot syndrome, fatigue, nausea, reduced appetite, and ...
Miriam Hussein, Anders Bonde Jensen
doaj   +1 more source